Costa, L. J., LeBlanc, T. W., Tesch, H., Sonneveld, P., Johnson, S. M. A., Vekeman, F., … DiBonaventura, M. (2024). An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma. In Blood (Vol. 144, pp. 2401–2401). American Society of Hematology. https://doi.org/10.1182/blood-2024-203920

Costa, Luciano J., Thomas W. LeBlanc, Hans Tesch, Pieter Sonneveld, Sarasa M. A. Johnson, Francis Vekeman, Patrick Hlavacek, et al. “An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma.” In Blood, 144:2401–2401. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-203920.

Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Johnson SMA, Vekeman F, et al. An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma. In: Blood. American Society of Hematology; 2024. p. 2401–2401.

Costa, Luciano J., et al. “An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 2401–2401. Crossref, doi:10.1182/blood-2024-203920.

Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Johnson SMA, Vekeman F, Hlavacek P, Meche A, Cislo P, Hughes D, Nador G, DiBonaventura M. An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma. Blood. American Society of Hematology; 2024. p. 2401–2401.